linjc16/ctgov huggingface dataset:
Surveying the Receptivity for Telemedicine Pre-operative Consultation in UZ Brussel.

Study Overview
=================
Brief Summary
-----------------
We will be surveying patients coming to UZ Brussels for their pre-operative consultation, how they feel about changing these consultations to teleconsultations.

Official Title
-----------------
Surveying the Receptivity for Telemedicine Pre-operative Consultation in UZ Brussel.

Conditions
-----------------
Remote Consultation

Intervention / Treatment
-----------------
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients presenting to a planned in-hospital pre-operative consultation at UZ Brussels. Exclusion Criteria: Language barrier Inability to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Survey group<br>Patients are asked to fill in a survey. | Other: Survey<br>* Patients are asked to fill in a survey concerning teleconsultations<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Willingness to have a teleconsultation: Survey | Would this person be willing to have a teleconsultation in stead of a consultation face to face | 4 months |
Effect of Januvia on Ghrelin and Other Gut Hormones in Patients With Diabetes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see the effect of Januvia on Ghrelin levels in patients with diabetes.

Official Title
-----------------
Effect of Januvia on Ghrelin and Other Gut Hormones in Patients With Diabetes

Conditions
-----------------
Type 2 Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Type 2 diabetes Exclusion Criteria: Renal failure Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients who on Januvia | |
| 2<br>Patients on Janumet (Combination of Januvia and Metformin) | |
| 3<br>Patients on Metformin | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
MIdazolam Versus MOrphine in Acute Pulmonary Edema (MIMO Trial)

Study Overview
=================
Brief Summary
-----------------
Acute pulmonary edema (APE) is a common condition in the emergency room, associated with considerable mortality. The use of intravenous morphine in the treatment of APE remains controversial and Benzodiazepines have been suggested as an alternative for morphine to relieving dyspnoea and anxiety in the patients with APE. The MIdazolan versus MOrphine in APE trial (MIMO) is a multicenter, prospective, open-label, randomized study designed to evaluate the efficacy and safety of morphine in patients with APE.

Official Title
-----------------
Study Design and Rationale of A Multicenter, Open-Labeled, Randomized Controlled Trial Comparing MIdazolam Versus MOrphine in Acute Pulmonary Edema: MIMO Trial

Conditions
-----------------
Acute Pulmonary Edema

Intervention / Treatment
-----------------
* Drug: Midazolam
* Drug: Morphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with acute pulmonary edema with dyspnoea and anxiety Exclusion Criteria: Patients with known severe liver disease. Patients with known severe renal disease. Patients with expectation of death from other illness during the course of the trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: midazolam<br>The dose of midazolam intravenously will be of 1 mg which may be repeated until a total dose of 3 mg. | Drug: Midazolam<br>* Dose use according to the product technical sheet<br>|
| Active Comparator: morphine<br>The dose of morphine intravenously is of 2-4 mg which may be repeated until a total dose of 8 mg if the patient continue suffering from severe anxiety or distress caused by APE | Drug: Morphine<br>* Dose use according to the product technical sheet<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-hospital Mortality | In hospital mortality | 28 days after of the hospitalization | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants That Required Invasive Mechanical Ventilation |  | Up to 1 week | 
| Length of Hospital Stay | Length of hospital stay | Up to 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute heart failure, morphine, midazolam, in-hospital mortality
Visceral Pain From the Upper Urinary Tract - a Trial on the Effect of Morphine and Oxycodone in Patients Undergoing PCNL

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the effect of oxynorm versus morphine after operation for kidney stone (PCNL). In addition the relationship between pain symptoms and referred sensory and trophic changes will be examined in the patients before and after the operation.Finally a blood sample is analysed to investigate pharmaca-genetics.

Detailed Description
-----------------
Primary outcome: the amount of opioid (morphine or oxynorm) used the first 4 hours postoperatively. Secondary outcome: side effect to the opioids, pain score, pain threshold to electrical stimulation and pressure before and after operation, pharmacogenetics, size of referred pain area.

Official Title
-----------------
Visceral Pain Originating From the Upper Urinary Tract - a Randomized Controlled Trial on the Effect of Morphine and Oxycodone in Patients Undergoing Percutaneous Nephrolithotomy (PCNL)

Conditions
-----------------
Kidney Stones

Intervention / Treatment
-----------------
* Drug: oxycodone
* Drug: morphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 Indication for PCNL Exclusion Criteria: Malignant disease in the upper urinary tract Allergy to morphine or oxycodone Use of opioids the last 48 hours before PCNL Pregnancy Nursing mothers Present JJ-stent in the ureter Previous urinary stone disease on the opposite site

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: oxycodone<br> | Drug: oxycodone<br>* intravenous according to patients weight, pn.<br>* Other names: oxynorm N02A A05;|
| Active Comparator: morphine<br> | Drug: morphine<br>* intravenous administration according to patients weight, pn.<br>* Other names: morphine SAD N02 AA 01;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amount of analgetics used |  | four hours postoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Side effects |  | four hours postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PCNL, oxycodone, morphine, visceral pain
Effect of Local Pamidronate in Preventing Bone Loss After Total Hip Arthroplasty

Study Overview
=================
Brief Summary
-----------------
The aims of the study are to determine whether pamidronate applied locally causes diminished periprosthetic bone loss and decreased rate of bone turnover compared to patients receiving placebo after cemented total hip arthroplasty (THA). The study design will be prospective, randomized, and blind. Periprosthetic bone mineral density (BMD) will be measured with dual energy X-ray absorptiometry (DXA) at the total periprosthetic area as well as at seven Gruen zones or regions of interest. DXA scans will be performed at one week (baseline), three months, and six months postoperatively. Mean values of biochemical markers of bone turnover, BMD, and baseline-normalized BMD values will be compared between the bisphosphonate and placebo groups at each time point. For all temporal measurements including bone markers, BMD and normalized BMD, mean values will be compared across each time point within a given group.

Official Title
-----------------
Phase 1 Study of the Effect of Local Pamidronate Application in Preventing Periprosthetic Bone Loss After Total Cemented Hip Arthroplasty

Conditions
-----------------
Arthroplasty, Mineral Density

Intervention / Treatment
-----------------
* Drug: pamidronate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with hip arthritis scheduled for total cemented hip arthroplasty Exclusion Criteria: pregnancy endoprosthesis on contralateral hip

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: pamidronate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Periprosthetic bone mineral density |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biochemical markers of bone turnover |  | 6 months |
Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation

Study Overview
=================
Brief Summary
-----------------
Currently, there is very little research to identify ways to decrease blood loss during D&E (dilation and evacuation) procedures. The objective is to determine whether routine use of intravenous oxytocin will improve bleeding outcomes at the time of D&E at 18-24-weeks gestation. To evaluate the hypothesis, investigators will perform a randomized, double-blinded, placebo-controlled trial. The patient will be followed until discharged from the postoperative care unit during which time patient satisfaction, pain score and postoperative bleeding will be assessed.

Official Title
-----------------
A Randomized Double-blinded Controlled Trial Comparing Dilation and Evacuation Outcomes With and Without Oxytocin Use

Conditions
-----------------
Abortion, Dilation and Evacuation, Hemorrhage, Blood Loss

Intervention / Treatment
-----------------
* Drug: intravenous oxytocin
* Drug: Intravenous Fluids and Electrolytes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Requesting pregnancy termination Intrauterine pregnancy at 18- to 24-weeks gestation Gestational-age to be confirmed by ultrasound Patients with fetal anomaly or intrauterine fetal demise that occurred at 18- to 24-weeks gestation Willing and able to understand and sign written informed consents in English or Spanish and comply with study procedures Exclusion Criteria: Ultrasound findings suggestive of placenta accreta Patients requiring preoperative misoprostol

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>500ml saline or lactated ringer without oxytocin added | Drug: Intravenous Fluids and Electrolytes<br>* 500 ml of inert IV fluid<br>|
| Active Comparator: Treatment group<br>Intravenous oxytocin mixed with saline or lactated ringer | Drug: intravenous oxytocin<br>* 30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate at Which Providers Intervene to Control Blood Loss During D&E Procedures. |  | During surgical procedure |
Physiological Examination of New Fighting Clothing During Exposure to Exercise Under Hot Conditions

Study Overview
=================
Brief Summary
-----------------
The use of fighting clothing under extreme heat conditions during rest and exercise, compromises the body's ability to maintain temperature within the narrow physiological range needed for regular function, and might lead to heat injury. Beside working and fighting clothing, the fighters also wear vests used for protection and equipment carrying, which leads to substantial reduction in effective dissipation area from the central region of the body. This fact is most substantial during exercise which increases metabolic heat production rate and leads to heat accumulation and rise in body temperature. Therefore the development of new textile technologies to allow rapid cooling during intervals is of great importance. This study is designed to physiologically examine new textile solutions, by evaluating the physiological stress induced during exercise under mild heat conditions.

Official Title
-----------------
Physiological Examination of New Fighting Clothing During Exposure to Exercise Under Hot Conditions

Conditions
-----------------
Clothing

Intervention / Treatment
-----------------
* Device: New Fighting Clothing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men Formerly fighters Healthy Without prior diseases including heart, vessel, respiratory and metabolic diseases or known use of medications experience in using fighting clothing VO2max > 50 ml/kg/min Exclusion Criteria: Incapacity to fulfill inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 28 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: All subjects<br>All subjects in this trial will receive the new fighting clothing while performing the study protocol | Device: New Fighting Clothing<br>* VO2max test Clothing examination- 2-hour walk in 6 kph/4% elevation under 30 degrees Celsius and 60% relative humidity<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body temperature | Using rectal thermometer | During intervention period (2 hours test) only | 
| Heart rate | Using heart rate watch | During intervention period (2 hours test) only |
Follow-up of Arthrosurface HemiCAP Implants

Study Overview
=================
Brief Summary
-----------------
Follow-up of Arthrosurface HemiCAP shoulder implants.

Detailed Description
-----------------
In summary, the investigators would like to contact all patients who have had HemiCAP implants done at CCF with at least 2 years of follow-up after their procedure. The investigators will use electronic or written means to alert the patients that they will be contacted by our team to discuss their surgery and any related issues. Once the appropriate consent is obtained, the investigators will use a brief telephone interview to ask the patients several questions regarding any re-operations or complications the patients have had since the index procedure.

Official Title
-----------------
Follow-up of Arthrosurface HemiCAP Implants

Conditions
-----------------
Orthopedic Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -Patients who had Arthrosurface (Franlin, MA) HemiCAP implants placed into their shoulders at the Cleveland Clinic Exclusion Criteria: Anyone who has not had ARthrosurface (Franlin, MA) HeiCAP implants placed into their shoulders at the Cleveland Clinic
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arthrosurface | survival curve for the implant | 2 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of revision surgeries | rate of revision surgeries | 2 year |
Pancreatectomy for NET: External Evaluation of WHO 2017 Grading System

Study Overview
=================
Brief Summary
-----------------
Aim: The aim of this study was to investigate the clinicopathological factors and to evaluate the prognostic accuracy of the new World Health Organization (WHO) 2017 grading system in pancreatic neuroendocrine tumor (PanNET) patients. Methods: Data collected between 1997 and December 2017 were analyzed. Histological grading and staging was based on the WHO 2017 grading system. Outcome after surgery and predictors of overall survival (OS) and disease free survival (DFS) were evaluated.

Official Title
-----------------
Outcome After Pancreatectomy for Neuroendocrine Tumor and Evaluation of the WHO 2017 Grading System: a Retrospective Multicentric Analysis of 138 Consecutive Patients.

Conditions
-----------------
Pancreatic Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: - patients with histologically proven neuroendocrine tumor located in pancreas who underwent pancreatic resection (by open, laparoscopic or robotic approach) even in case of distant metastasis at time of surgery, with no previous or concurrent malignancy. Exclusion criteria: - Patients with tumors diagnosed as adenocarcinoma with scattered neuroendocrine cells or with focal neuroendocrine component were excluded of this study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease-free survival at 5 years | Disease-free survival (percentage of patients without recurrence) at 5 years. Disease-free survival (DFS) (time from diagnosis to time of first radiological evidence of local, regional, or distant relapse, or death due to any cause) | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival at 5 years | Overall survival (OS) (time from diagnosis until death, regardless of cause) | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
neuroendocrine tumor, Survival, WHO 2017 grading system, pancreatectomy, Laparoscopy, Postoperative outcomes
Effect of Corticosteroid Injections on Blood Glucose

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to measure the effect of various corticosteroids administered to the shoulder, knee and hip joints in diabetic patients on resultant blood glucose readings.

Detailed Description
-----------------
The purpose of this study is to measure the effect of various corticosteroids administered to the shoulder, knee, and hip joints in diabetic patients on resultant blood glucose readings. Corticosteroid injections (CSI) are frequently used in orthopedic settings in order to treat a wide array of orthopedic issues, including osteoarthritis, bursitis, tendinitis, and many others. The effect of diabetes on the musculoskeletal system and its role in orthopedic disease has been well-documented. Current evidence demonstrates that corticosteroids, even when administered through a local musculoskeletal injection, can lead to temporary increases in blood glucose. Ultrasound guidance was not explicitly used in any of the studies examining the impact of steroids on blood glucose. The utilization of ultrasound guidance has been shown to increase accuracy when performing injections into the subacromial space as well as the glenohumeral joint when compared to palpation/landmark-guided injections.

Official Title
-----------------
Corticosteroid Injections Administered Under Ultrasound Guidance to Diabetic Patients and the Effect on Blood Glucose

Conditions
-----------------
Diabetes Mellitus, Steroid Diabetes, Shoulder Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Known diabetic patients ages 40-75 undergoing clinically indicated standard of care corticosteroid shoulder, knee and hip joint injection Ability to perform daily blood glucose testing Can receive and send text messages Exclusion Criteria: Previous joint arthroplasty Corticosteroid injection at other sites in the body within the past month Systemic corticosteroid within the last month other than asthma inhaler Anyone who are unable to read and/or understand English Pregnant women (self-report)

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diabetic patients receiving a corticosteroid injection of their shoulder, knee or hip joints.<br>There are no study-related interventions for this study. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in blood glucose measures | Reported daily glucose measures from baseline to two week after injection | Baseline & 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes, Corticosteroids, Injection, Shoulder, Pain